logo
Plus   Neg
Share
Email

Alnylam Pharma Q3 Loss Narrows On Strong Revenue Growth

Alnylam Pharmaceuticals Inc. (ALNY) reported Thursday that its third-quarter net loss narrowed to $208.5 million or $1.92 per share from last year's loss of $245.3 million or $2.43 per share last year.

Adjusted net loss was $162.5 million, or $1.50 per share, compared to net loss of $157.3 million, or $1.56 per share a year earlier.

Total revenues surged to $70.06 million from $2.07 billion a year ago.

In pre-market activity, Alnylam shares were gaining around 1.4 percent to trade at $88.50.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT